Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry - 1 Jun 2010

Kasuga Kensaku, Tokutake Takayoshi, Ishikawa Atsushi, Uchiyama Tsuyoshi, Tokuda Takahiko, Onodera Osamu, Nishizawa Masatoyo, Ikeuchi Takeshi

Abstract excerpt

BACKGROUND: The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to alpha-Synuclein
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Peptides

Share to Enzyme-Linked Immunosorbent Assay

Share to Lewy Body Disease

Share to Peptide Fragments

Share to tau Proteins

Source

Identifiers

PMID: 20522869
DOI: 10.1136/jnnp.2009.197483

Genes

SNCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20522869-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.PMID 20522869Read ↗

CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.Semantic proximity Read ↗

Dementia with Lewy bodies.Semantic proximity Read ↗

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.Semantic proximity Read ↗

Alzheimer’s disease copathology in dementia with Lewy bodies is associated with astroglial α-synucleinopathySemantic proximity Read ↗

Differential expression of α‐synuclein isoforms in dementia with Lewy bodiesSemantic proximity Read ↗

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer DiseaseSemantic proximity Read ↗

Beta-synuclein gene alterations in dementia with Lewy bodies.Semantic proximity Read ↗

α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.Semantic proximity Read ↗

Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.Semantic proximity Read ↗

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.Semantic proximity Read ↗

Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?Semantic proximity Read ↗

Lewy body pathology in late-onset familial Alzheimer's disease: a clinicopathological case series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.